AMENDMENTS TO THE CLAIMS

In the claims, please cancel claims 2, 3, 11-13, 16 and 17, and amend claim 18 as follows:

- 1. (original) A process for delivering a polynucleotide complexed with a compound into an extravascular muscle cell of a mammal, comprising:
 - a) mixing the polynucleotide and a polymer to form a complex wherein the zeta potential of the complex is not positive;
 - b) inserting the polynucleotide into a mammalian blood vessel, in vivo;
 - c) increasing the permeability of the blood vessel;
 - d) passing the complex through the blood vessel;
 - e) delivering the complex into the mammalian muscle cell; and,
 - f) expressing the polynucleotide.
- 2. (canceled)
- 3. (canceled)
- 4. (original) The process of claim 1 wherein increasing the permeability of the vessel consists of increasing pressure against vessel walls.
- 5. (original) The process of claim 4 wherein increasing the pressure consists of increasing a volume of fluid within the vessel.
- 6. (original) The process of claim 5 wherein increasing the volume consists of inserting the polynucleotide in a solution into the vessel.
- 7. (original) The process of claim 1 wherein the muscle cell is a skeletal muscle cell.
- 8. (original) The process of claim 7 wherein the skeletal muscle cell is a limb muscle cell.
- 9. (original) The process of claim 1 wherein the compound is selected from the group consisting of histone, PEI, cationic lipid, poly-L-lysine, histone-lipid, histone-polyamine, and protamine.
- 10. (original) The process of claim 1 wherein the zeta potential of the complex is negative.
- 11-13. (cancelled)
- 14. (original) A process for delivering a polynucleotide complexed with a compound into an extravascular liver cell of a mammal, comprising:
 - a) mixing the polynucleotide and a polymer to form a complex wherein the zeta potential of the complex is not positive;
 - b) inserting the polynucleotide into a mammalian blood vessel, in vivo;
 - c) increasing the permeability of the blood vessel;
 - d) passing the complex through the blood vessel;

- e) delivering the complex into the mammalian muscle cell; and,
- f) expressing the polynucleotide.
- 15. (original) The process of claim 14 wherein the liver cell consists of an hepatocyte.
- 16. (canceled)
- 17. (canceled)
- 18. (currently amended) The process of claim 47 14 wherein increasing the permeability of the vessel consists of increasing pressure against vessel walls.
- 19. (original) The process of claim 18 wherein increasing the pressure consists of increasing a volume of fluid within the vessel.
- 20. (original) The process of claim 19 wherein increasing the volume consists of inserting the polynucleotide in a solution into the vessel.
- 21. (original) The process of claim 14 wherein the compound is selected from the group consisting of histone, PEI, cationic lipid, poly-L-lysine, histone-lipid, histone-polyamine, and protamine.
- 22. (original) The process of claim 14 wherein the zeta potential of the complex is negative.